A standing ovation: Tarlatamab + durvalumab as frontline maintenance in ES-SCLC, phase 3 DeLLphi-305:
📈 Median OS: 21.1 vs 12.7 mo (HR, 0.42)
📈 Median PFS: 7.4 vs 1.9 mo (HR, 0.34)
🎯 ORR: 26.4% vs 4.1%

Data presented at the @myESMO #ESMO26 Presidential Symposium support a new SOC. #lcsm #medtwitter #oncology @sands_jacob @DanaFarber

https://www.onclive.com/view/dellphi-305-data-support-frontline-maintenance-tarlatamab-plus-durvalumab-as-a-new-soc-in-es-sclc